Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1

Conditions

Breast Neoplasms 630Prostatic Neoplasms 373Neoplasms 306Carcinoma, Non-Small-Cell Lung 218Lung Neoplasms 205Colorectal Neoplasms 178Multiple Myeloma 145Pancreatic Neoplasms 136Leukemia, Myeloid, Acute 130Neoplasm Metastasis 124Melanoma 117Brain Neoplasms 115Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Glioblastoma 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 99Uterine Cervical Neoplasms 96Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 92Colonic Neoplasms 84Stomach Neoplasms 80Rectal Neoplasms 80Sarcoma 78Recurrence 78Urinary Bladder Neoplasms 77Triple Negative Breast Neoplasms 76Carcinoma, Renal Cell 76Lymphoma 72Hematologic Neoplasms 68Lymphoma, Non-Hodgkin 67

Interventions

Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Erdheim-Chester Disease × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡